Therapeutic Options to Refractory Alopecia Areata

Article Sidebar

PDF
Published: Jan 10, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i1-06
Keywords:
...

Main Article Content

Alejandra Jeraldine González Barajas
Universidad Autónoma de Guadalajara
Paola Chávez Contreras
Universidad Autónoma de Guadalajara

Abstract

Alopecia areata is a relapsing chronic condition that causes hair loss without leaving scars. Alopecia areata's clinical history varies; the condition may resolve spontaneously, persist, recur, or advance. Alopecia areata sufferers are treated in numerous ways, including: Information about the progression and prognosis of alopecia areata Consideration of medical treatment continuation; Treatment selection (for individuals who desire to continue treatment); Provision of psychological support resources; and Discussion of aesthetic possibilities.

Article Details

How to Cite
González Barajas, Alejandra Jeraldine, and Paola Chávez Contreras. 2023. “Therapeutic Options to Refractory Alopecia Areata”. International Journal of Medical Science and Clinical Research Studies 3 (1):25-27. https://doi.org/10.47191/ijmscrs/v3-i1-06.
Issue
Vol. 3 No. 1 (2023): Volume 03 Issue 01 January 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Gao, Y., Huo, S., Sun, M., Zhang, C., Wang, J., Gao, J., ... & Lv, Y. (2022). Evaluation of several immune and inflammatory indicators and their association with alopecia areata. Journal of Cosmetic Dermatology, 21(7), 2995-3001.

II. Davey, L., Clarke, V., & Jenkinson, E. (2019). Living with alopecia areata: an online qualitative survey study. British Journal of Dermatology, 180(6), 1377-1389.

III. Moretz, D. (2021). OHSU Drug Effectiveness Review Project Summary Report–Atopic Dermatitis.

IV. Gilhar, A., Keren, A., & Paus, R. (2019). JAK inhibitors and alopecia areata. The Lancet, 393(10169), 318-319.

V. Winthrop, K. L., & Cohen, S. B. (2022). Oral surveillance and JAK inhibitor safety: The theory of relativity. Nature Reviews Rheumatology, 18(5), 301-304.

VI. Crowley, E. L., Fine, S. C., Katipunan, K. K., & Gooderham, M. J. (2019). The use of Janus kinase inhibitors in alopecia areata: a review of the literature. Journal of cutaneous medicine and surgery, 23(3), 289-297.

VII. Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., ... & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insight, 1(15).

VIII. Luo, Y., Alexander, M., Gadina, M., O’Shea, J. J., Meylan, F., & Schwartz, D. M. (2021). JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. Journal of Allergy and Clinical Immunology, 148(4), 911-925.

IX. Olsen, E. A., Kornacki, D., Sun, K., & Hordinsky, M. K. (2020). Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. Journal of the American Academy of Dermatology, 82(2), 412-419.

X. AREATA, A. 7th World Congress for Hair Research.

XI. Sachdeva, M., Witol, A., Mufti, A., Maliyar, K., & Yeung, J. (2021). Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review. Journal of Cutaneous Medicine and Surgery, 25(4), 451-452.

XII. Olamiju, B., & Craiglow, B. G. (2021). Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls. Journal of the American Academy of Dermatology, 84(6), 1689-1691.

XIII. Amor, K. T., Ryan, C., & Menter, A. (2010). The use of cyclosporine in dermatology: part I. Journal of the American Academy of Dermatology, 63(6), 925-946.

XIV. Messenger, A. G., McKillop, J., Farrant, P., McDonagh, A. J., Sladden, M., Hughes, J., ... & Mohd Mustapa, M. F. (2012). British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British journal of dermatology, 166(5), 916-926.

XV. Gupta, P., Verma, K. K., Khandpur, S., & Bhari, N. (2019). Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata. Indian Journal of Dermatology, 64(4), 292.

XVI. Açıkgöz, G., Çalışkan, E., Tunca, M., Yeniay, Y., & Akar, A. (2014). The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutaneous and Ocular Toxicology, 33(3), 247-252.

XVII. Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., ... & Fortuna, M. C. (2019). Italian Guidelines in diagnosis and treatment of alopecia areata.

XVIII. Ramos, P. M., Anzai, A., Duque-Estrada, B., Melo, D. F., Sternberg, F., Santos, L. D. N., ... & Mulinari-Brenner, F. (2021). Consensus on the treatment of alopecia areata–Brazilian Society of Dermatology. Anais Brasileiros de Dermatologia, 95, 39-52.

XIX. Ellis, C. N., Brown, M. F., & Voorhees, J. J. (2002). Sulfasalazine for alopecia areata. Journal of the American Academy of Dermatology, 46(4), 541-544.

XX. Nasimi, M., Ghandi, N., Abedini, R., Mirshamsi, A., Shakoei, S., & Seirafi, H. (2019). Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Archives of Dermatological Research, 311(8), 607-613.